Get the Stockscreener App
0.6703
5.53%
-0.0392
After Hours:
.70
0.0297
+4.43%
Acurx Pharmaceuticals Inc stock is traded at $0.6703, with a volume of 143.07K.
It is down -5.53% in the last 24 hours and down -8.19% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
See More
Previous Close:
$0.7095
Open:
$0.7
24h Volume:
143.07K
Relative Volume:
0.42
Market Cap:
$13.09M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-0.5829
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-20.94%
1M Performance:
-8.19%
6M Performance:
-68.08%
1Y Performance:
-77.35%
1-Day Range:
$0.67
$0.7199
1-Week Range:
$0.67
$0.85
52-Week Range:
$0.669
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.6703 | 13.09M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - Longview News-Journal
What's Next for Acurx's Antibiotic Pipeline? March Earnings Call Will Reveal Development Progress - StockTitan
Biotech Alert: Searches spiking for these stocks today - TipRanks
Acurx’s ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down - Nasdaq
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the - Digital More
Acurx's ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com South Africa
Acurx's ibezapolstat shows selective bacterial targeting - Investing.com
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI - Longview News-Journal
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative… - Informazione.it
ACXP stock touches 52-week low at $0.67 amid market challenges - Investing.com UK
Acurx Pharmaceuticals secures Japanese patent for antibiotics By Investing.com - Investing.com South Africa
Acurx Pharmaceuticals secures Japanese patent for antibiotics - Investing.com India
Dual Victory for Acurx: Japanese Patent Grant Follows EMA's Green Light for Phase 3 Antibiotic Trial - StockTitan
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming - StreetInsider.com
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Drops By 52.2% - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decline in Short Interest - Armenian Reporter
Acurx Pharmaceuticals Says Selling Shareholders May Sell 2.6 Million Shares -January 31, 2025 at 05:06 pm EST - Marketscreener.com
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update - Defense World
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH) - ACCESS Newswire
Geode Capital Management LLC Increases Stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Acurx Pharmaceuticals Inc (ACXP) - SETE News
HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals (NASDAQ: ACXP) Announces $2.5 Million Registered Direct Offering - Defense World
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 - Investing.com
Acurx pharmaceuticals director Joseph Scodari acquires $25,000 in stock - Investing.com
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 By Investing.com - Investing.com UK
Acurx Pharmaceuticals director buys $9,999 in common stock - Investing.com
Acurx Pharmaceuticals director Robert DeLucca buys $49,999 in stock By Investing.com - Investing.com South Africa
ACXP stock touches 52-week low at $0.72 amid market challenges - Investing.com Canada
Acurx Pharmaceuticals Secures $2.5M Financing Through Direct Offering and Warrant Placement - StockTitan
Form 424B5 Acurx Pharmaceuticals, - StreetInsider.com
SEC Form 424B5 filed by Acurx Pharmaceuticals Inc. - Quantisnow
Acurx to sell 2.46M shares at $1.015 in registered direct offering - MSN
Acurx gains EMA support for ibezapolstat Phase 3 trial By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals announces $2.5 million registered direct offering - MSN
Acurx gains EMA support for ibezapolstat Phase 3 trial - Investing.com
Acurx's Ibezapolstat Secures EMA Backing for Phase 3 C. Difficile Treatment Program - StockTitan
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? - Yahoo Finance
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Increase in Short Interest - Defense World
Acurx Pharmaceuticals to Present Latest Antibiotic Developments at 2025 Microcap Conference - StockTitan
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025January 30, 2025 - Eagle-Tribune
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - Kilgore News Herald
Acurx prepares for Phase 3 trials in C. difficile treatment By Investing.com - Investing.com Canada
Acurx prepares for Phase 3 trials in C. difficile treatment - Investing.com India
Acurx's Breakthrough CDI Antibiotic Advances Toward Global Phase 3 Trial Following FDA Green Light - StockTitan
ACXP stock touches 52-week low at $0.79 amid market challenges - Investing.com UK
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now - MSN
ACXP stock touches 52-week low at $1.01 amid market challenges - Investing.com Canada
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):